Pfizer expanding API plant in Australia

Pfizer ($PFE) will invest about $15.7 million (AU$21 million) to expand a plant in Adelaide, Australia, to increase the capacity of the active ingredient for Neulasta. No new jobs, however, are associated with the expansion, ABC in Australia reports. Site director Tony Mulcahy told the news service that the Adelaide facility makes the intermediate for pegfilgrastim, which is sent to a Pfizer plant in Croatia that does the fill-finish work. Story

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.